WO2009046876A3 - Utilisation d'un peptide en tant qu'agent thérapeutique - Google Patents

Utilisation d'un peptide en tant qu'agent thérapeutique Download PDF

Info

Publication number
WO2009046876A3
WO2009046876A3 PCT/EP2008/008143 EP2008008143W WO2009046876A3 WO 2009046876 A3 WO2009046876 A3 WO 2009046876A3 EP 2008008143 W EP2008008143 W EP 2008008143W WO 2009046876 A3 WO2009046876 A3 WO 2009046876A3
Authority
WO
WIPO (PCT)
Prior art keywords
lys
leu
ala
val
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/008143
Other languages
English (en)
Other versions
WO2009046876A2 (fr
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mondobiotech Laboratories AG
Original Assignee
Mondobiotech Laboratories AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Laboratories AG filed Critical Mondobiotech Laboratories AG
Publication of WO2009046876A2 publication Critical patent/WO2009046876A2/fr
Publication of WO2009046876A3 publication Critical patent/WO2009046876A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pediatric Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)

Abstract

La présente invention concerne l'utilisation de la combinaison des composés peptidiques Asp-Val-Ala-His-Gly-lle-Leu-Asn-Glu-Ala-Tyr-Arg-Lys-Val-Leu-Asp-Gin- Leu-Ser-Ala-Gly-Lys-His-Leu-Gln-Ser-Leu-Val-Ala et His-Ser-Asp-Gly-lle-Phe-Thr- Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu- Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 en tant qu'agent polythérapeutique destiné à la prophylaxie et/ou au traitement du cancer, d'une maladie cardiaque et vasculaire, d'une maladie infectieuse, d'une maladie fibreuse, d'une maladie inflammatoire, d'une maladie neurodégénérative ou d'une maladie auto-immune.
PCT/EP2008/008143 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique Ceased WO2009046876A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017756.3 2007-09-11
EP07017759 2007-09-11
EP07017759.7 2007-09-11
EP07017756 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009046876A2 WO2009046876A2 (fr) 2009-04-16
WO2009046876A3 true WO2009046876A3 (fr) 2009-11-05

Family

ID=40549642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008143 Ceased WO2009046876A2 (fr) 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique

Country Status (1)

Country Link
WO (1) WO2009046876A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117618528B (zh) * 2023-12-01 2024-10-01 广东医科大学 一种方格星虫多肽srp及其在制备治疗急性肾损伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06228002A (ja) * 1993-01-29 1994-08-16 Takeda Chem Ind Ltd Ｐａｃａｐを含有するセクレトグラニンιι産生促進剤
WO1996009064A1 (fr) * 1994-09-22 1996-03-28 The Administrators Of The Tulane Educational Fund Procede et preparation pharmaceutique pour la prevention et le traitement des lesions cerebrales
US20060247166A1 (en) * 2005-04-27 2006-11-02 Nidek Co., Ltd. Eye disease treating agent and method for treating eye disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06228002A (ja) * 1993-01-29 1994-08-16 Takeda Chem Ind Ltd Ｐａｃａｐを含有するセクレトグラニンιι産生促進剤
WO1996009064A1 (fr) * 1994-09-22 1996-03-28 The Administrators Of The Tulane Educational Fund Procede et preparation pharmaceutique pour la prevention et le traitement des lesions cerebrales
US20060247166A1 (en) * 2005-04-27 2006-11-02 Nidek Co., Ltd. Eye disease treating agent and method for treating eye disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199437, Derwent World Patents Index; AN 1994-299702, XP002540926, HOSOYA ET AL: "Accelerator of secretogranin II which contains PACAP - useful for treatment of Alzheimer's disease" *

Also Published As

Publication number Publication date
WO2009046876A2 (fr) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2009033821A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033797A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043518A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
IL184125A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2007135026A3 (fr) Ptéridines substituées
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2009033819A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2006058867A3 (fr) Pteridines substituees pour le traitement de maladies inflammatoires
IL210953A0 (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
WO2010094734A3 (fr) Procédés d'identification de composés utiles pour le diagnostic et le traitement de maladies liées à une inflammation
WO2009033813A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043525A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033814A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033818A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046875A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033820A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033809A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033816A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046872A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043523A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043519A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009074498A8 (fr) Nouvelle utilisation médicale de l'orotate de propionate de 3-(2,2,2-triméthylhydrazine)
WO2006089664A3 (fr) Imidazoles substitues par heterocyclylamide
WO2008009426A9 (fr) Dérivés de 5-cyano-prostacycline utilisés comme agents dans le traitement de maladies auto-immunes
WO2009033812A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08837399

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08837399

Country of ref document: EP

Kind code of ref document: A2